Nektar Therapeutics (NKTR) Earns Buy Rating from Analysts at HC Wainwright

Equities researchers at HC Wainwright assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report issued on Monday, August 7th, MarketBeat Ratings reports. The firm set a “buy” rating and a $31.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 71.84% from the company’s current price.

Several other research firms also recently issued reports on NKTR. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. Jefferies Group LLC set a $25.00 price objective on Nektar Therapeutics and gave the company a “buy” rating in a research note on Saturday, April 22nd. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, August 1st. Finally, Roth Capital set a $31.00 price objective on Nektar Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 11th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.10.

Shares of Nektar Therapeutics (NKTR) traded down 2.06% on Monday, hitting $18.04. 1,075,725 shares of the stock traded hands. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The stock has a 50 day moving average of $20.49 and a 200-day moving average of $18.57. The stock’s market cap is $2.82 billion.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. During the same period in the prior year, the company earned ($0.36) EPS. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts expect that Nektar Therapeutics will post ($0.94) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/nektar-therapeutics-nktr-receives-new-coverage-from-analysts-at-hc-wainwright-updated.html.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 8,389 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $21.04, for a total transaction of $176,504.56. Following the transaction, the senior vice president now directly owns 51,961 shares in the company, valued at approximately $1,093,259.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO John Nicholson sold 3,177 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $61,379.64. Following the transaction, the chief operating officer now owns 224,066 shares in the company, valued at $4,328,955.12. The disclosure for this sale can be found here. Insiders have sold a total of 237,629 shares of company stock valued at $4,820,217 in the last three months. Insiders own 6.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Flinton Capital Management LLC boosted its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of Nektar Therapeutics by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 17,050 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 460 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock worth $1,236,000 after buying an additional 500 shares in the last quarter. LS Investment Advisors LLC boosted its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares in the last quarter. Finally, World Asset Management Inc boosted its position in shares of Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 539 shares in the last quarter. Hedge funds and other institutional investors own 93.02% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply